KT
Kinaset Therapeutics is developing targeted respiratory therapeutics aimed at treating severe asthma in patients with intractable diseases. Their lead asset utilizes a novel mechanism of action to improve lung function and reduce exacerbations, enhancing the quality of life for affected individuals.
Updated 20 months ago
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Kinaset Therapeutics is developing targeted respiratory therapeutics aimed at treating severe asthma in patients with intractable diseases. Their lead asset utilizes a novel mechanism of action to improve lung function and reduce exacerbations, enhancing the quality of life for affected individuals.